The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease-Reference-Cited by-同舟云学术

The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease

Published:2020-05-26 Issue:9 Volume:15 Page:993-1003
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Ettcheto Miren¹²³⁴,Busquets Oriol¹²³⁴,Sánchez-Lopez Elena⁴⁵⁶,Cano Amanda⁴⁵⁶,Manzine Patricia R.¹³⁴⁷,Verdaguer Ester³⁴⁸,Olloquequi Jordi⁹,Auladell Carme³⁴⁸,Folch Jaume²³,Camins Antoni¹³⁴⁹

Affiliation:

1. Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain

2. Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain

3. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain

4. Institute of Neuroscience, University of Barcelona, Barcelona, Spain

5. Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain

6. Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain

7. Department of Gerontology, Federal University of São Carlos (Ufscar), São Carlos, Brazil

8. Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain

9. Laboratory of Cellular and Molecular Pathology, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile

Funder

Spanish Ministry of Science and Innovation

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2020.1767580

Reference89 articles.

1. Parkinson disease

2. Parkinson disease

3. Pathogenesis and pathophysiology of functional (psychogenic) movement disorders